Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis

Yanli Hou; Bin Wu

doi:10.1002/cac2.12110

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis

Cancer Communications ◽

10.1002/cac2.12110 ◽

2020 ◽

Vol 40 (12) ◽

pp. 743-745

Author(s):

Yanli Hou ◽

Bin Wu

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

First Line Treatment

Download Full-text

PCN77 COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Value in Health ◽

10.1016/j.jval.2020.04.1579 ◽

2020 ◽

Vol 23 ◽

pp. S37

Author(s):

X. Li ◽

G. Wudong ◽

Y. Wang

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

First Line Treatment

Download Full-text

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1607 ◽

2016 ◽

Vol 19 (3) ◽

pp. A153

Author(s):

W Cheng ◽

JW Hay

Keyword(s):

Pancreatic Cancer ◽

Cost Effectiveness ◽

Societal Perspective ◽

Cost Effectiveness Analysis ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

The Us ◽

First Line Treatment

Download Full-text

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

International Urogynecology Journal ◽

10.1007/s00192-018-3662-y ◽

2018 ◽

Vol 29 (8) ◽

pp. 1221-1221

Author(s):

Abdelmageed Abdelrahman

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Onabotulinumtoxin A ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-020-0200-9 ◽

2020 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Herbert H. Loong ◽

Carlos K. H. Wong ◽

Linda K. S. Leung ◽

S. C. Tan ◽

Jason Jen ◽

...

Keyword(s):

Hong Kong ◽

Cost Effectiveness ◽

Standard Of Care ◽

Cost Effectiveness Analysis ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma

Oral Oncology ◽

10.1016/j.oraloncology.2019.04.022 ◽

2019 ◽

Vol 94 ◽

pp. 80-85 ◽

Cited By ~ 6

Author(s):

Xudong Chen ◽

Weiting Liang ◽

Ning Wan ◽

Li Zhang ◽

Yunpeng Yang ◽

...

Keyword(s):

Cost Effectiveness ◽

Nasopharyngeal Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Metastatic Nasopharyngeal Carcinoma ◽

First Line Treatment

Download Full-text

A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell

Value in Health ◽

10.1016/j.jval.2015.09.1110 ◽

2015 ◽

Vol 18 (7) ◽

pp. A446 ◽

Cited By ~ 1

Author(s):

T Piha ◽

D Barbosa ◽

L Fahham

Keyword(s):

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis

Cancer ◽

10.1002/(sici)1097-0142(19961201)78:11<2366::aid-cncr15>3.0.co;2-z ◽

1996 ◽

Vol 78 (11) ◽

pp. 2366-2373 ◽

Cited By ~ 21

Author(s):

Andrea Messori ◽

Sabrina Trippoli ◽

Paola Becagli ◽

Enrico Tendi

Keyword(s):

Cost Effectiveness ◽

Ovarian Carcinoma ◽

Lifetime Cost ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Advanced Ovarian Carcinoma ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text